Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer - Wikidata - wikimedia - TriplyDB

Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer

Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer

http://www.wikidata.org/entity/Q39069931

about

Roles of PTEN with DNA Repair in Parkinson's Disease Valproic Acid Increases CD133 Positive Cells that Show Low Sensitivity to Cytostatics in Neuroblastoma The tumor suppressive role of CAMK2N1 in castration-resistant prostate cancer.Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells.PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.CAMK2N1 inhibits prostate cancer progression through androgen receptor-dependent signaling.SKP2 inactivation suppresses prostate tumorigenesis by mediating JARID1B ubiquitination.The Anti-Apoptotic Role of Berberine in Preimplantation Embryo In Vitro Development through Regulation of miRNA-21.Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo.Histone Deacetylase Inhibitors Inhibit the Proliferation of Gallbladder Carcinoma Cells by Suppressing AKT/mTOR Signaling Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression.PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.Geroconversion: irreversible step to cellular senescence Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways Effect of PI3K/Akt Signaling Pathway on the Process of Prostate Cancer Metastasis to Bone.Histone deacetylases function as a novel potential therapeutic target for cancer.HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.VS-5584 mediates potent anti-myeloma activity via the upregulation of a class II tumor suppressor gene, RARRES3 and the activation of Bim.Dual inhibition of AKT-mTOR and AR signaling by targeting HDAC3 in PTEN- or SPOP-mutated prostate cancer.HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression

P2860

Q26744483-07E93EAE-0429-4970-9DC5-C312667DAB56 Q28554068-D8B21E1E-0ECD-4D93-BABB-F7DA9F1225E3 Q33976977-8C653F89-68E8-4448-8F3F-AF0C2F519441 Q34104052-F229CEB6-DC99-4C5B-A7BB-AA046433EB4E Q34199935-332704C9-57FE-4496-AE27-86EDD2A9EEBC Q34786431-0CB4A7DA-DA9E-43D4-A875-0B2542E15B04 Q35176138-1BBA23CB-F9EB-4FB5-B23B-8B400E44D0B7 Q35652724-044224EB-42E7-4221-A040-8B6360348E42 Q35741591-B096B790-7310-409D-8453-37959583FA01 Q35749913-0C1306B1-253C-4012-857E-BDD79A800466 Q35857477-E512C8E2-A837-46CB-9FFF-C52785105EE3 Q35948581-EDD63847-4E02-4275-84A1-62A572A87E1C Q36152474-BD8069F3-BBB6-4230-8DC9-C85EF01DBFE3 Q36186369-D1762932-AFDD-4592-AF13-3B6994CCA4B5 Q36997524-48CD84E6-09E1-4CA2-9E58-2BD7CCA344FA Q37645002-3A9632B0-1A99-4D99-8640-DDEEB6B36920 Q37718328-3439F895-DA47-4C3A-B9D1-D96463F6E066 Q38781061-04532CC4-A8B6-47F1-B9E0-E217D436C703 Q38908331-DE959548-8BE7-4358-AB7D-344DA7956F05 Q38984146-35CD2DCB-C2E4-41FD-B339-4BCB6F9A825F Q41874831-96D92C59-92EE-4D1C-A75A-C88B9AF324A8 Q47107700-5BF1016D-11F6-42F8-B7C1-E14C33A370BF Q55337031-B9D56C49-904F-4F52-8D39-1C69AC5E4E32 Q58773654-302FDB8B-C426-4C3F-AFA2-228DB9967C92

P2860

Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer

http://www.wikidata.org/entity/Q39069931

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Combinatorial antitumor effect ...... cient model of prostate cancer

@en

Combinatorial antitumor effect ...... ient model of prostate cancer.

@nl

type

label

Combinatorial antitumor effect ...... cient model of prostate cancer

@en

Combinatorial antitumor effect ...... ient model of prostate cancer.

@nl

prefLabel

Combinatorial antitumor effect ...... cient model of prostate cancer

@en

Combinatorial antitumor effect ...... ient model of prostate cancer.

@nl

P1433

Q39069931-F0A938DF-9A37-4215-961B-8AD7D0065F4D

P1476

Q39069931-2E55BA7C-B04E-428A-BB53-E2696A01EA00

P2093

Q39069931-14970AB0-FE60-45F6-92FD-1B39E0AB367F

Q39069931-31DF0C51-0459-4828-BFD8-E8CDB9110804

Q39069931-50D65229-F71F-437D-BB30-380E14ED7698

Q39069931-65E6CCA6-F432-40CA-8470-5928432EF7A2

Q39069931-DB070374-2A97-4249-B4F3-0D278B3F4295

Q39069931-EEE5C9A3-0601-4FD9-AEBC-246A62C17936

Q39069931-FF5EAE0C-3DFE-47A0-9D85-B4D996F5874D

P2860

Q39069931-0835FFC1-8059-49DA-AEC7-89B18156C0E0

Q39069931-08647FAE-2A0A-4ACF-BC07-EE23C9683B81

Q39069931-08A3AA85-9D2E-43D5-B72F-059FDD589BD8

Q39069931-08DA97D0-BF64-42B6-BD09-1183AA215059

Q39069931-0A2595AE-E41B-431B-AEBB-3A4D05EE8A67

Q39069931-0BEB8B1A-1333-474B-9FBA-3951A4DB1014

Q39069931-10FD86B8-BF76-41A2-B1A5-CC7A5A86F067

Q39069931-13EC30F1-427E-43F8-AC94-763DAD2089DD

Q39069931-2205AF11-3698-4D68-9C6A-0004F4B88378

Q39069931-27B244E1-5718-4FB8-AF5F-7EB80225BFAA

P304

Q39069931-2EEEC93A-4DE4-428D-9027-CC009EBF8FDC

P31

Q39069931-38E06050-12FA-426D-B57F-B759BA7D23A7

P356

Q39069931-A56B499C-7D15-400C-88CF-8F58CD8BDF20

P407

Q39069931-C34D6BCE-57A4-4B9A-9A3E-5B1F62B39BB6

P433

Q39069931-8C2404B6-34E0-4851-979D-F436715D459F

P478

Q39069931-CA072359-78D3-4D80-AB82-2D681852D4DC

P577

Q39069931-A081630A-DBED-41DE-AA82-6DA3D0A71755

P5875

Q39069931-CF493579-189D-4A4C-9BAB-EAF14277205A

P698

Q39069931-BED46A57-8357-4A57-9BC1-F9DDF1C07874

P932

Q39069931-C8211B87-3014-4FED-8E06-F3A747AE7BD1

P356

ONCOTARGET.1314

P1433

P1476

Combinatorial antitumor effect ...... cient model of prostate cancer

@en

P2093

Alejandro Godoy

http://www.w3.org/2001/XMLSchema#string

Elena Lasorsa

http://www.w3.org/2001/XMLSchema#string

Gizzou Azabdaftari

http://www.w3.org/2001/XMLSchema#string

Leigh Ellis

http://www.w3.org/2001/XMLSchema#string

Roberto Pili

http://www.w3.org/2001/XMLSchema#string

Sheng Yu Ku

http://www.w3.org/2001/XMLSchema#string

Swathi Ramakrishnan

http://www.w3.org/2001/XMLSchema#string

P2860

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor

Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Anticancer activities of histone deacetylase inhibitors

Increased survival with enzalutamide in prostate cancer after chemotherapy

P304

2225-2236

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.1314

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258104046

http://www.w3.org/2001/XMLSchema#string

P698

24163230

http://www.w3.org/2001/XMLSchema#string

P932

3926822

http://www.w3.org/2001/XMLSchema#string